Corcept trades GR-II antagonist royalties for non-dilutive cash from Pharmakon
This article was originally published in Scrip
Corcept Therapeutics has sold a total of $45 million worth of royalties for the recently launched Cushing's syndrome drug Korlym (mifepristone 300mg tablets) and any of its next-generation drugs in the same GR-II antagonist class to Pharmakon Advisors for $30 million.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.